Table 1.
Summary of relapse prevention studies of flupentixol decanoate (FD)
| Study | Study design | Sample (n) duration | Stabilisation | Randomisation (n) | Other antipsychotics | Determinant of treatment failure |
|---|---|---|---|---|---|---|
| Agrup-Andersson et al. (1974) | RCT | Stable, female outpatients (56) 6 months | 3 months—5 years | Continue dose (29) or halve dose (27) | Yes | Deterioration according to global rating or refusal to continue |
| Chiliza et al. (2016) | Open-label non-comparison | First episode, inpatient and outpatients (207) 12 months | During study period | N/A | No | Relapse in patients who initially responded |
| Cookson (1987) | RCT | Patients previously unresponsive to doses < 100 mg/2 weeks, improved on dose > 100 mg/2 weeks (18) 44 weeks | At least 3 months | Continue dose (9) or halve dose (9) | Yes | Relapse |
| Dencker et al. (1980) | RCT | Outpatients, previously stabilised on clopenthixol decanoate or flupentixol LAI (30) 12 months | None | Continue/switch to flupentixol palmitate (30) | No | Dropout due to unsatisfactory effect |
| Gottfries and Green (1974) | Follow-up/mirror image study | Outpatients, previously initiated on FD (58) up to 6 years | N/A | N/A | Not stated | Relapse |
| Johnson et al. (1987) | RCT | Outpatients, stabilised on FD < 40 mg/2 weeks (59) 12 months | At least 6 months | Continue dose (31) or halve dose (28) | No | Relapse |
| Kelly et al. (1977) | RCT | Outpatients stabilised on phenothiazine injections (15) 9 months | During first 9 weeks | FD 20 mg/3 weeks (15) or 40 mg/3 weeks (15) | No | Relapse or pregnancy |
| Knights et al. (1979) | RCT | Inpatients in acute relapse (28) 6 months | None | FD 40 mg/3 weeks (28) | No | Relapse or readmission to ward or day hospital |
| Laux et al. (2010) | Prospective cohort study | Inpatients and outpatients, initiated on FD in routine practice (94) 24 weeks | N/A | N/A | Yes | Relapse |
| McCreadie et al. (1988) | RCT—1-year follow-up | Patients responsive to oral treatment during acute first episode, subsequently randomised to FD (12) 12 months | Over 5 weeks | FD | Yes | Never discharged from hospital, re-admitted within 2 weeks of discharge, refusal of medication |
| Pach et al. (1998), Finkbeiner et al. (1998) | RCT | Outpatients who achieved remission within 3–12 weeks on FD dosed by treating psychiatrist (18) 12 months | 3–12 weeks | FD 10 mg/2 weeks (19) or 20 mg/2 weeks (25) or flexible dosing (18) | Yes | Relapse |
| Pinto et al. (1979) | RCT | Outpatients stabilised on fluphenazine or FD (31) 18 months | At least 6 months | Continue/switch to FD | Yes | Dropout from trial |
| Shajahan et al. (2010) | Retrospective record review | Newly initiated patients (43 initiated onto FD) mean 13.6 months | N/A | N/A | Yes | Discontinuation due to inefficacy |
| Steinert et al. (1986) | RCT | Inpatients, acutely symptomatic (16) 12 months | None | FD 20–40 mg every 2 weeks | No | Dropout from trial |
| Wistedt (1981), Wistedt et al. (1982) | RCT | Outpatients, stabilised on FD (16) 24 weeks | At least 3 months | Continue FD or discontinue FD | No | Relapse |
| Wistedt and Ranta (1983) | RCT | Patients who had relapsed after drug withdrawal (17) 100 weeks | None | FD (dose as per previous dose requirement) | Yes | Dropout from trial |